A prospective multicenter study assessing consolidation with 90Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy
Latest Information Update: 17 Sep 2020
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Cyclophosphamide; Doxorubicin; Fludarabine; Prednisone; Rituximab; Vincristine
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 17 Sep 2020 New trial record